Cancer Prevention Research Audrey Hepburn AM No Deadline
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Prevention Research 2, 531, June 1, 2009. Published Online First May 26, 2009;
doi: 10.1158/1940-6207.CAPR-08-0185
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Perspective on this Article
Right arrow All Versions of this Article:
1940-6207.CAPR-08-0185v1
2/6/531    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Fu, H.
Right arrow Articles by You, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fu, H.
Right arrow Articles by You, M.
Related Collections
Right arrow Preclinical Intervention
Right arrow Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms
Right arrowKey Article

Research Articles

Lung Cancer Inhibitory Effect of Epigallocatechin-3-Gallate Is Dependent on Its Presence in a Complex Mixture (Polyphenon E)

Huijing Fu1, Jun He2, Fan Mei1, Qi Zhang2, Yukihiko Hara3, Seto Ryota2, Ronald A. Lubet4, Ruth Chen1, Da-Ren Chen1 and Ming You2,3

Authors' Affiliations: 1 Department of Energy, Environmental and Chemical Engineering, Washington University of St. Louis and 2 Department of Surgery, Campus Box, The Alvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri; 3 Mitsui Norin Co., Ltd., Shizuoka, Japan; and 4 Chemoprevention Agent Development Research Group, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Ming You, Department of Surgery and Alvin J. Siteman Cancer Center, Washington University in St. Louis, 660 South Euclid Avenue, Campus Box 8109, 10130 Wohl Clinic, St. Louis, MO 63110. Phone: 314-362-9294; Fax: 314-362-9366; E-mail: youm{at}wudosis.wustl.edu.


Green tea has been shown to exhibit cancer-preventive activities in preclinical studies. However, (–)-epigallocatechin-3-gallate (EGCG) alone was shown to be ineffective in preventing lung tumorigenesis in mice by aerosol administration. In this study, Polyphenon E and Polyphenon E without EGCG were administered by aerosol delivery to A/J mice 2 weeks after carcinogen treatment and continuing daily throughout the remainder of the study (20 weeks). An improved aerosol delivery system with a custom-built atomizer, an efficient solvent remove system, and a nose-only exposure chamber was used to provide aerosols with stable size distribution. There were no significant differences in the size distributions of Polyphenon E and Polyphenon E without EGCG. With a relatively low dose level (4.19 mg/kg), Polyphenon E decreased tumor multiplicity by 53%, whereas Polyphenon E without EGCG at the same dose failed to inhibit lung carcinogenesis. These results indicate that aerosol administration can be an effective approach in chemoprevention study, and aerosolized Polyphenon E can significantly inhibit pulmonary adenoma formation and growth in A/J mice. Furthermore, in aerosolized form, EGCG, which is thought to be the most active component of Polyphenon E, has to be present with other tea catechins to show chemopreventive activity on lung tumorigenesis.

Key Words: aerosol • Polyphenon E • EGCG • mouse • lung tumorigenesis • chemoprevention


Key Article

Epigallocatechin 3-Gallate and Green Tea Catechins: United They Work, Divided They Fail
Ann M. Bode and Zigang Dong
Cancer Prevention Research 2009 2: 514-517. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
A. S. Tsao, D. Liu, J. Martin, X.-m. Tang, J. J. Lee, A. K. El-Naggar, I. Wistuba, K. S. Culotta, L. Mao, A. Gillenwater, et al.
Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions
Cancer Prevention Research, November 1, 2009; 2(11): 931 - 941.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.